The additional subcutaneous administration option expands Takeda's offering in this space, showing dedication to the HAE community while providing individualized treatment options to support ...

has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of YESINTEK, an Ustekinumab ...

today announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA) to conduct its pivotal Phase 2B/3, multi-center, randomized, double-blind, placebo ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

The European Medicines Agency (EMA) on Friday recommended scrapping approval for a drug used to prolong gestation, citing a "possible but unconfirmed" risk of cancer. Healthcare ...

today announced that the European Medicines Agency (EMA) approved the Company’s Clinical Trial Application (CTA) for CLN-978. The Phase 1 clinical trial will assess CLN-978 in patients with ...

Stockley Park, UK – 6 June 2024 – Kite, a Gilead Company, today announced that the European Medicines Agency has approved a Type II variation to the Summary of Product Characteristics (SmPC) for its ...

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA ... Pertuzumab has been approved in various countries and regions in ...

INDIANAPOLIS — A European ... Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines Agency committee ...